{
    "nctId": "NCT03947151",
    "briefTitle": "Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer",
    "officialTitle": "Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining FSH and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Invasive Ductal Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 8,
    "primaryOutcomeMeasure": "Number of follicles 16 to 20 mm in diameter obtained with estradiolemia <500 pg /mL",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with invasive ductal carcinoma breast cancer, whatever the hormonal receptor expression profile\n* Age : 18 - 40 years\n* Presence of 2 ovaries\n* Antral follicular count between 12 and 30 on both ovaries and/or recent measurement of serum anti-M\u00fcllerian hormone between 1.5 and 4 ng / mL (between Day-25 and Day0)\n* Indication of chemotherapy\n* Indication of preservation of fertility according to an oocyte vitrification technique after controlled ovarian stimulation (COS)\n* Patient in the early follicular phase of the cycle at the start of the controlled ovarian stimulation (COS) (absence of follicle\\> 10 mm in ultrasound and estradiolemia \\<50 pg / mL)\n* Oncology team agreement for the controlled ovarian stimulation (COS)\n* Social insured patient\n* Patient who gave her consent to participate by signing the consent of the study\n\nExclusion Criteria:\n\n* Patient in late follicular phase or luteal phase\n* Known hypersensitivity to one of the constituents of Firmagon\u00ae",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}